A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Week Dose-Ranging Study to Assess the Efficacy and Safety of Etrasimod in Japanese Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.
Inclusion Criteria:
Exclusion Criteria:
Hirosaki-shi, Aomori 036-8545, Japan
Hirosaki-shi, Aomori 036-8563, Japan
Hirosaki-shi, Aomori 036-8563, Japan
Kashiwa-shi, Chiba 277-0871, Japan
Nagareyama-shi, Chiba 270-0116, Japan
Toon-shi, Ehime 791-0295, Japan
Kitakyushu-shi, Fukuoka 802-8555, Japan
Kitakyushu-shi, Fukuoka 802-8561, Japan
Kitakyushu-shi, Fukuoka 807-1266, Japan
Kurume-shi, Fukuoka 830-0011, Japan
Kutakyushu-shi, Fukuoka 802-8555, Japan
Onga-gun, Fukuoka 807-0051, Japan
Ota-shi, Gunma 373-8585, Japan
Fukuyama-shi, Hiroshima 720-0822, Japan
Fukuyama-shi, Hiroshima 720-8520, Japan
Asahikawa-shi, Hokkaido 070-8610, Japan
Higashiibaraki-gun, Ibaraki 311-3193, Japan
Koga-shi, Ibaraki 306-0232, Japan
Sashima-gun, Ibaraki 306-0433, Japan
Toride-shi, Ibaraki 302-0014, Japan
Tsuchiura-shi, Ibaraki 300-0028, Japan
Yokohama, Kanagawa 234-0054, Japan
Yokkaichi- Shi, Mie-ken 510-0891, Japan
Yokkaichi-shi, Mie-ken 510-8561, Japan
Nagaoka-shi, Niigata 940-2085, Japan
Hirakata-shi, Osaka 573-1191, Japan
Kishiwada-shi, Osaka 596-0042, Japan
Iruma-gun, Saitama 350-0495, Japan
Saitama-shi, Saitama 330-0074, Japan
Bunkyo-ku, Tokyo 113-8519, Japan
Kodaira-shi, Tokyo 187-8510, Japan
Minato-ku, Tokyo 108-8642, Japan
Shinjuku-ku, Tokyo 169-0073, Japan